Verwendung von Serotonin-Antagonisten bei der Behandlung von Apoplexia cerebri
申请人:Troponwerke GmbH & Co. KG
公开号:EP0360077A2
公开(公告)日:1990-03-28
Wirkstoffe, mit Serotonin-agonistischer Wirkung, die bevorzugt an 5HT1A-Rezeptoren binden, werden zur Herstellung von Arzneimitteln zur Behandlung von Apoplexia cerebri verwendet.
PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
申请人:ALS Mountain Llc
公开号:EP2983473A2
公开(公告)日:2016-02-17
NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
申请人:Chen Chien-Hung
公开号:US20120183600A1
公开(公告)日:2012-07-19
The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.